return
  • Maintain contact with the treatment supporter to ensure any adverse event is reported and handled in a timely manner.

  • It is generally not necessary to monitor liver or renal function or platelet counts for patients on first-line drugs unless abnormalities at baseline exist or there are clinical reasons to obtain them.

  • Click here for a table that provides guidance on a symptom-based approach to monitoring anti-TB drugs, and the correct clinical response to side effects.
forward